CSIMarket Company Name, Ticker, Suppliers, else..
 
Iridex Corp  (NASDAQ: IRIX)
 
Price: $0.7211 $-0.01 -1.219%
Day's High: $0.7281000018119812 Week Perf: 1.56 %
Day's Low: $ 0.72 30 Day Perf: -12.06 %
Volume (M): 14,753 52 Wk High: $ 1.65
Volume (M$): $ 0 52 Wk Avg: $1.11
Open: $0.72 52 Wk Low: $0.70



 Market Capitalization (Millions $) 13
 Shares Outstanding (Millions) 17
 Employees 93
 Revenues (TTM) (Millions $) 51
 Net Income (TTM) (Millions $) -4
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Business Description


Iridex Corp is a medical device company that specializes in developing, manufacturing, and marketing laser-based medical solutions for ophthalmology and other medical specialties. The company's products primarily focus on the treatment of eye diseases, including glaucoma and retinal diseases. Their laser systems are used by ophthalmologists worldwide for various procedures, such as the removal of abnormal tissues, coagulation of blood vessels, and treatment of retinal conditions. Iridex Corp aims to provide innovative and advanced solutions to enhance patient care and improve outcomes in the field of ophthalmology.


   Company Address: 1212 Terra Bella Avenue Mountain View 94043 CA
   Company Phone Number: 940-4700   Stock Exchange / Ticker: NASDAQ IRIX


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
EDAP        6.03% 
ESTA        3.41% 
FEMY        6.16% 
LNSR   -1.73%    
OSUR   -2.7%    
SRTS   -1.22%    
• View Complete Report
   



Management Announcement

“Iridex’s Fight for Survival: Will Innovation or Investment Steer the Company Back to Health”

Published Mon, Apr 14 2025 8:05 PM UTC

In a landscape marked by rapid technological advancements and fierce competition, Iridex Corporation (NASDAQ: IRIX), a prominent player in the medical device industry, has found itself at a crossroads. Founded with the vision of revolutionizing the treatment of glaucoma and retinal diseases through innovative laser-based medical systems and delivery devices, the company is n...
Management Announcement

Cash Infusion Amid Crisis: Can Iridex Innovate Its Way Back to Financial Health,

Published Wed, Mar 19 2025 1:15 PM UTC

ArticleIn a bold move that underscores both the potential and precarious state of Iridex Corporation (NASDAQ: IRIX), the Mountain View-based company recently closed a strategic investment deal worth $10 million, backed by Novel Inspiration International Co. Ltd. This investment raises questions about Iridex’s financial sustainability and its ability to capitalize on groun...
Management Announcement

“Iridexs Medical Breakthroughs: A Silver Lining in the Storm of Stock Market Struggles”,

Published Fri, Mar 14 2025 11:00 AM UTC

Iridex Faces Stock Market Turbulence Amid Groundbreaking Innovation in Glaucoma TreatmentBy CSI Market MOUNTAIN VIEW, Calif. — In the face of considerable stock price volatility, Iridex Corporation (NASDAQ: IRIX), a recognized leader in laser-based medical systems for glaucoma and retinal diseases, has publicly addressed its recent financial struggles while simultaneo...
Clinical Study

Iridexs Breakthrough in Glaucoma Treatment Amidst Financial Challenges A Balancing Act of Innovation and Market Pres...

Published Wed, Dec 18 2024 9:05 PM UTC

The management of glaucoma, a leading cause of irreversible blindness worldwide, has reached a new horizon with the announcement from Iridex Corporation regarding a groundbreaking five-year study on MicroPulse Transscleral Laser Therapy (TLT), also known as Transscleral Cyclophotocoagulation. This study, recently published in the esteemed journal Ophthalmology Therapy , und...
Shares

Iridex Announces Convertible Note Financing: Bolstering Innovations in Laser-based Medical Systems

Published Mon, Aug 5 2024 12:01 PM UTC



Iridex Corporation, a global leader in providing laser-based medical systems and devices for the treatment of glaucoma and retinal diseases, has recently announced the execution of definitive agreements for a private placement financing. The financing involves a senior convertible promissory note with Lind Global Asset Management IX LLC, managed by The Lind Partner...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.25
Price to Sales (Expected) -
Price to Book 3.45
PEG (TTM) -

Financial Strength Current
Quick Ratio 0.36
Working Capital Ratio 1.82
Leverage Ratio (MRQ) 6.49
Total Debt to Equity 1.04
Interest Coverage (TTM) -
Debt Coverage (TTM) -

Per Share Current
Earnings (TTM) -0.2 $
Revenues (TTM) 2.93 $
Cash Flow (TTM) -
Cash 0.27 $
Book Value 0.21 $
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) 548,860
Net Income per Employee (TTM) -38,140
Receivable Turnover Ratio (TTM) 7.49
Inventory Turnover Ratio (TTM) 3.8
Asset Turnover Ratio (TTM) 1.81

Profitability Ratios Current
Gross Margin (MRQ) 34.19 %
Operating Margin (MRQ) -8.19 %
Net Margin (MRQ) -10.07 %
Net Cash Flow Margin (MRQ) 0 %
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) -
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -



Iridex's Segments
Cyclo G Six    60.19 % of total Revenue
Retina    97.98 % of total Revenue
Cyclo G6    35.73 % of total Revenue
Service Contract Revenues Distribution Rights    2.2 % of total Revenue
US    87.52 % of total Revenue
Europe Middle East and Africa    54.07 % of total Revenue
Asia Pacific    43.36 % of total Revenue
Americas excluding the U S    8.95 % of total Revenue





Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.